Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to KRYS. [ FAQ on what and how to ask] For non-KRYS questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 2100 Wharton Street, Suite 701, Pittsburgh, PA, United States, 15203
Employees: 295
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Founder, Chairman, President & CEO
Founder, President of R&D and Director
Executive VP & Chief Accounting Officer
EVP, General Counsel & Corporate Secretary
Vice President of North American Sales & Marketing
Senior Vice President of Corporate Development
Senior Director & Head of US Human Resources
Executive VP & Head of International
Senior Vice President of Clinical Development
Senior VP & Head of US Commercial
My Watchlist
